8-K: Picard Medical Rings NYSE Opening Bell

Picard Medical, Inc. celebrated its transition to the public markets by ringing the NYSE Opening Bell on December 18, 2025, highlighting its leadership in total artificial heart technology.

Summary

• Picard Medical, Inc., parent company of SynCardia Systems LLC, rang the Opening Bell at the New York Stock Exchange on December 18, 2025.
• This event marks the company's transition to the public markets and its continued commitment to advancing total artificial heart therapy for patients with end-stage heart failure.
• SynCardia Systems LLC develops, manufactures, and commercializes the SynCardia Total Artificial Heart (STAH), which is the world's first and only commercially available artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
• The STAH has been implanted over 2,100 times at hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally.

Sentiment

Score: 9

Explanation: The filing announces a significant positive corporate milestone (ringing the NYSE bell for becoming a public company) and highlights the company's leadership and future plans for its life-saving medical technology.

Positives

• Successful transition to a publicly traded company, marked by ringing the NYSE Opening Bell.
• Commitment to advancing total artificial heart technology, including the fully implantable Emperor system.
• SynCardia Total Artificial Heart is the world's first and only commercially available artificial heart approved by both the U.S. FDA and Health Canada.
• Extensive global adoption with over 2,100 implants performed in 27 countries.
• Building on decades of clinical leadership in life-sustaining total artificial heart technology.

Risks

• Forward-looking statements involve risks and uncertainties that could cause actual results to differ from the forward-looking statements.
• Numerous conditions, many of which are beyond the control of the Company, are set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC.

Future Outlook

Picard Medical plans to strengthen its ability to advance its artificial heart platform, including the fully implantable Emperor system, and continue building on decades of clinical leadership to create long-term value.

Management Comments

• "We are proud to mark Picard Medicals transition to a newly public company."
• "Our technology has supported patients worldwide and becoming a public company strengthens our ability to advance our artificial heart platform including the fully implantable Emperor system."
• "This marks an important next phase as we build on decades of clinical leadership pioneering the worlds first life-sustaining total artificial heart, advancing our next-generation technology and creating long-term value."

Industry Context

Picard Medical, through its subsidiary SynCardia Systems LLC, maintains a leading position in the medical device industry, specifically in the niche market of total artificial hearts. Its SynCardia Total Artificial Heart is uniquely positioned as the only FDA and Health Canada approved commercially available device in its category, indicating a significant competitive advantage and barrier to entry for potential competitors.

Comparison to Industry Standards

• SynCardia Total Artificial Heart is the world's first and only commercially available artificial heart approved by both the U.S. FDA and Health Canada, setting a high standard for regulatory achievement in the field.
• With over 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart globally, demonstrating unparalleled market penetration and clinical experience compared to any other similar technology.

Stakeholder Impact

• Shareholders: Positive impact due to the company's transition to public markets, focus on long-term value creation, and continued advancement of leading medical technology.
• Patients: Positive impact through the company's commitment to advancing total artificial heart therapy for end-stage heart failure and developing next-generation systems like the Emperor.
• Employees: Positive impact from the company's growth, market leadership, and continued innovation in a critical medical field.

Next Steps

• Advance the artificial heart platform, including the fully implantable Emperor system.
• Continue building on decades of clinical leadership in pioneering life-sustaining total artificial hearts.
• Advance next-generation technology.
• Create long-term value.

Key Dates

Keywords

Picard Medical, SynCardia, Total Artificial Heart, NYSE, Public Company, Medical Device, Heart Failure, FDA Approved, Health Canada Approved, Emperor System